The Mediator complex (Mediator) plays pivotal roles in activating transcription by RNA polymerase II (Pol II), but relatively little is known about its roles in repression. Here, we identified the histone arginine methyltransferase PRMT5 and WD-repeat protein 77/methylosome protein 50 (WDR77/MEP50) as Mediator cyclindependent kinase (CDK)-interacting proteins, and studied the roles of PRMT5 in the transcriptional regulation of C/EBPβ target genes. First, we purified CDK8-and CDK19-containing complexes from HeLa nuclear extracts and subjected these purified complexes to mass spectrometric analyses. These experiments revealed that two Mediator CDKs, CDK8 and CDK19, individually interact with PRMT5 and WDR77, and their interactions with PRMT5 cause transcriptional repression of C/EBPβ target genes by regulating symmetric dimethylation of histone H4 arginine 3 (H4R3me2s) in the promoter regions of those genes. Furthermore, the recruitment of the DNA methyltransferase DNMT3A correlated with H4R3 dimethylation potentially leading to DNA methylation at the promoter proximal region and tight inhibition of preinitiation complex formation. In vertebrates, C/EBPβ regulates many genes involved in immune responses and cell differentiation. These findings shed light on the molecular mechanisms of the repressive roles of Mediator CDKs in transcription of C/EBPβ target genes, and might provide clues that enable future studies of the functional associations between Mediators and epigenetic regulation.
In eukaryotes, the expression of proteincoding genes is elaborately regulated primarily at the level of transcription by RNA polymerase II (Pol II) in collaboration with chromatin regulation (1) (2) (3) . Certain cofactors, including the Mediator complex (Mediator), are involved not only in direct regulatory roles during transcription but also in epigenetic regulatory events such as histone modifications and chromatin remodeling.
Mediator was first identified by genetics in the budding yeast Saccharomyces cerevisiae. Several yeast proteins, oliginally named SRBs (suppressors of RNA polymerase B), were subsequently found to be the Mediator subunits. Mutations in the SRB proteins suppress the defects caused by deletion of the C-terminal domain (CTD) heptapeptide repeats of the largest subunit of RNA polymerase II (4) . Subsequent studies revealed that Mediator relieves squelching (activator-induced inhibition of transcription) during in vitro transcription in crude nuclear extracts (5) . Yeast Mediator was purified by Kornberg and colleagues (6) . Mediator has also been identified in and purified from mammals, in which it connects nuclear hormone receptors with the transcription machinery (7) (8) (9) (10) (11) .
A recently proposed unified nomenclature for all Mediator subunits includes 34 MED proteins (MED1-MED31, MED1L, MED12L, and MED13L) as well as two CDK proteins (CDK8 and CDK19) and their common counterpart cyclin C (12, 13) . CDK8 is a compornent of a CDK/Cyclin submodule, functions as a serine/threonine kinase, and is required for various developmental events, but not for cell survival, in metazoa (14, 15) . According to the current consensus, CDK8 generally functions as a negative regulatory component of Mediator (16, 17) . However, recent studies have shown that CDK8 also plays a positive role in transcriptional regulation (18, 19) . We observed that at least two Mediator subcomplexes contain human CDK8, yet exert opposite effects on transcriptional activation. Thus, it is clear that CDK8 plays multiple roles in transcriptional regulation (20) (21) (22) (23) . Another kinase subunit of the human Mediator complex, CDK19 (formerly CDK11), was recently identified using multidimensional protein identification technology (MudPIT) (24) . Human CDK19 shares a high degree of amino acid sequence identity with CDK8. In previous studies, we demonstrated that CDK19 forms a CDK8-independent Mediator complex (25) . Furthermore, we observed that CDK19 is expressed in a tissue-specific manner, whereas CDK8 is ubiquitously expressed (26) . DNA microarray analysis of the target genes of each CDK complex revealed extensive overlap in their target gene preferences (26) . Therefore, we decided to explore the idea that Mediators play a pivotal role in transcriptional regulation (19, 25) .
To gain insight into the molecular mechanisms of transcriptional repression by CDK8 and/or CDK19, we treated HeLa cells with phorbol 12-myristate 13-acetate (PMA) and examined the effects on C/EBPβ target genes . The transcriptional activator C/EBPβ is a regulator of acute-phase responses such as innate and adaptive immunity, senescence, and receptor tyrosine kinase/Ras-mediated tumorigenesis (27) (28) (29) (30) (31) (32) (33) (34) (35) . The transcription activities of C/EBPβ are controlled both by protein-protein interactions with transcriptional cofactors and by posttranscriptional modifications (31, 32) . Phosphorylation of C/EBPβ triggers a conformational change in this protein that correlates with Mediator subtype exchange (27) . This finding indicates that there are differences between the Mediator subtypes with respect to transcriptional regulation; however, the functional role of each Mediator subtype during transcriptional regulation remains unclear.
In addition to performing functional studies, we attempted to isolate CDK8-and/or CDK19-interacting proteins from HeLa cells. We identified novel functional interactions between the two CDK subunits and the histone arginine methyltransferase PRMT5 and its functionally interacting partner, WD-repeat protein 77 (WDR77, also called methylosome protein 50, MEP50). Both CDK-containing Mediator complexes contained PRMT5 and WDR77, and they exhibited histone H4-specific arginine methyltransferase activity in vitro. Our results demonstrate that CDK8 and CDK19 recruit PRMT5 to the C/EBPβ-inducible gene promoters, and that PRMT5 represses their transcription through symmetric dimethylation of histone H4 arginine 3 (H4R3me2s). The accumulated evidence supports a model in which the Mediators themselves regulate chromatin structure (36) (37) (38) . In addition, H4R3me2s and PRMT5 itself interact with DNA methyltransferase 3a (DNMT3A) to repress gene transcription (39) . Finally, we show that DNMT3A is recruited to the C/EBPβ-inducible gene promoters in a manner that depends on the CDKs. Based on these results, we propose a model in which Mediators participate in epigenetic regulation in a process that is essential for transcriptional regulation.
EXPERIMENTAL PROCEDURES
Cell Lines and siRNA-mediated CDK Knockdown-Cell lines stably expressing HA/FLAG-tagged (HF-) CDK8 or CDK19 stably expressing cell lines were established previously (25) . Normal HeLa S3 and CDKexpressing cells were maintained in DMEM supplemented with 5% calf serum at 37°C in 5% CO 2 . For PMA induction, we treated HeLa S3 cells with 25 ng/ml PMA for 2 h at 37°C. To deplete endogenous CDK8 and/or CDK19, we used synthetic siRNA pools targeting each gene.
Non-target control siRNA (siNC) (D-001810-10-05, Dharmacon) and siRNAs against CDK8 (L-003242-00-0005, Dharmacon) and CDK19 (L-004689-00-0005, Dharmacon) were transfected at a concentration of 5 nM by using the Lipofectamine RNAi MAX transfection reagent (Invitrogen). After transfection, cells were cultured for 72 h, and then subjected to ChIP or RT-qPCR analysis. After washing, immunocomplexes were eluted by incubation with 100 µl of elution buffer (1% SDS, 100 mM NaHCO 3 ) for 1 h at room temperature, and the eluates were collected. Crosslinks were reversed by overnight incubation at 65°C. Next, the eluate was treated with RNaseA for 1 h at 37°C, followed by treatment with Proteinase K for 2 h at 37°C. For qPCR, DNA templates were purified using the QIAquick PCR Purification Kit (Qiagen), and the purified DNA was quantified using SYBR ® Premix Ex Taq™ II (TaKaRa) on an Mx3000P QPCR system (Stratagene). Three hundred fifty nanograms of total RNA purified from siRNAtransfected cells using the Nucleo Spin RNA II kit (TaKaRa) was subjected to reversetranscription (RT) using PrimeScript™ RT Master Mix (TaKaRa). Synthesized cDNA was measured using SYBR ® Premix Ex Taq™ II (TaKaRa) on an Mx3000P QPCR system (Stratagene).
Antibodies
Primer Sets for qPCR-The following primer sets were used in ChIP analyses:
The following primer sets were used in qPCR analyses:
Purification of HF-CDK8-and HF-CDK19-containing
Mediator ComplexesNuclear extracts were prepared from each tagged CDK-expressing HeLa S3 cell line. Nuclear extracts were equilibrated with Buffer C(0. Affinity-pulldown Analyses-The human PRMT5 cDNA (FLJ90770AAAN) and human WDR77 cDNA (FLJ12798AAAN) were obtained from NBRC (NITE Biological Resource Center, Japan). To generate plasmids compliant with the Gateway system, we converted the pTriEX-2 protein-expression plasmid (Millipore) into a Gateway-compliant plasmid using the Gateway® Vector Conversion System (Invitrogen). The cDNAs were subcloned into the converted pTriEX-2 vector using the Gateway system to yield constructs suitable for expression of S-tagged PRMT5 (S-PRMT5) or WDR77 (S-WDR77) in HeLa S3 cells and bacteria. Purified HF-CDK8, HF-CDK19, S-PRMT5, or S-WDR77 expression plasmid (3 µg) was transfected into HeLa S3 cells in a 10-cm dish using the Lipofectamine™ LTX reagent (Invitrogen). After a 24-h incubation, cells were harvested by scraping, and then lysed in BC(0.3) containing 0.05% NP-40 by sonication (UR-21P, TOMY) for 10 sec. Cell lysates were incubated with 20 µl of S-protein agarose (Novagen) for 6 h at 4°C. After four washes with 1 ml BC(0.3) containing 0.05% NP-40, precipitated proteins were subjected to Western blotting.
GST-pulldown
Analyses-Bacterially expressed GST-tagged CDK8 or CDK19 (500 ng) was tethered on a Glutathione-Sepharose resin (GE Healthcare) and incubated for 2 h at 4°C with 200 ng bacterially expressed S-PRMT5 or S-WDR77 in 500 µl of BC(0.1) (100 mM KCl, 20 mM HEPES·KOH [pH 7.9], 20% (v/v) glycerol, 0.5 mM EDTA, 50 mM PMSF, 2 µg/ml antipain, 2 µg/ml aprotinin, 1 µg/ml leupeptin, 0.8 µg/ml pepstatin, 0.5 mM EGTA, and 10 mM 2-mercaptoethanol) containing 0.05% NP-40. For S-PRMT5, precipitates were washed three times with 1 ml of BC(0.1) containing 0.05% NP-40, and for S-WDR77 precipitates were washed three times with 1 ml of BC(0.3) containing 0.05% NP-40. Finally, bound proteins were analyzed by Western blotting using an anti-S-tag antibody. (Sigma-Aldrich). Methylated histones were loaded onto an 18% acrylamide gel, electrophoresed, and subjected to Western blotting using anti-H4R3me2s and anti-Histone H4 antibodies.
In Vitro Histone Methyltransferase (HMT)
For fluorography analyses, equimolar amounts of purified complex and histones were incubated with 40 kBq of [ 3 H]-SAM for 1 h at 30°C. Methylated histones were separated by 18% polyacrylamide gel electrophoresis. Protein bands were stained with Coomassie brilliant blue (CBB), and the gels were equilibrated in water and then incubated with Enlight fluorographic enhancer (EnerGene) for 1h at room temperature. After drying, the gels were exposed to X-ray film (Fuji film) for 2 weeks at -80°C.
Microarray analyses of gene expression results after CDK8 and CDK19 double
knockdown-HeLa S3 cells were seeded on 6-well plate at 4 × 10 4 cells/well in 2ml of antibiotic-free DMEM medium 24h before transfection. siRNA at a final concentration of 20nM was transfected using Lipofectamine 2000 (Invitrogen). After culturing for 48h, transfection medium was changed to fresh antibioticcontaining medium. Transfected cells were incubated for additional 12h and then RNA was prepared using RNeasy columns (Qiagen). Purified RNA (5 µg) was subjected to gene expression analysis using Human Genome U133 Plus 2.0 (Affymetrix) arrays followed by characterizations using the GeneSpring (Agilent) and Pathway Analysis (Ingenuity) software. In this analysis, we employed two individual siRNA against each CDK (CDK8 and CDK19) and three replicates of each condition. The entire set of microarray dataset has been deposited in the public database Gene Expression Omnibus (GEO) and the assigned accession number is GSE45210.
RESULTS

CDK8 and CDK19 Dissociate from C/EBPβ-target
Gene Promoters upon Activation-Mediator complexes have been classified into at least two distinct subtypes, the large canonical holo-Mediator complex (LMediator; for simplicity, henceforth designated as Mediator) and the small core Mediator complex (S-Mediator). Mediator characteristically contains four submodules: head, middle, tail, and CDK/Cyclin. S-Mediator uniquely possesses the additional subunit MED26, but lacks the CDK/Cyclin submodule (40, 41) . Previously, based on in vitro transcription studies, Mediator was thought to act as a negative transcriptional regulator, and SMediator as a positive regulator (11) 
To study the mechanisms of transcriptional repression, we focused on Mediator's key enzymatic components, the CDK8 and CDK19 subunits. Previous reports demonstrated that CDK8 is released from C/EBPβ-target gene promoter regions upon activation by C/EBPβ (27, 42) , but the mechanism of CDK8 transcriptional repression is still unclear. To investigate the repressive functions of the two CDKs, we used C/EBPβ-inducible transcription in the HeLa S3 cell line as our model system, and focused on the C/EBPβ-target genes IL-8 and TNFα, as well as IL-1β and IL-12A (43, 44) , as repression targets of CDK8 and CDK19. We activated C/EBPβ by adding the phorbol ester, phorbol 12-myristate 13-acetate (PMA). PMA first activates protein kinase C (PKC), which activates the MAP kinase (MAPK) signaling pathway: ultimately, activated MAPK phosphorylates C/EBPβ, and this phosphorylation leads to activation of C/EBPβ transcriptional activity in NIH3T3 and U937 cells (35) . PMA treatment triggered transcription of the C/EBPβ-target genes IL-8 and TNFα (Fig. 1, A and B) . We also performed chromatin immunoprecipitation (ChIP) assays to analyze the localizations of C/EBPβ, CDK8, and CDK19 on the promoter regions of the target genes (Fig. 1, C and D) . In these studies, we detected both CDK8 and CDK19 proteins with an anti-CDK8 antibody because this antibody crossreacts with CDK19 in addition to CDK8 (26) ; therefore, the ChIP signals from this antibody are designated as CDK8/19 hereafter. Consistent with previous reports (35) , PMA treatment facilitated C/EBPβ recruitment to the promoter regions of its target genes and triggered Pol II transcriptional activation (CTD phosphorylation) (Fig. 1, C and D) . At each promoter, CDK8/19 signals were decreased by PMA treatment. This finding indicates that the dissociation of the Mediator CDKs (CDK8/19) from the activated promoters was caused by C/EBPβ-dependent transcriptional activation.
CDK8 and CDK19 also dissociate from several other genes targeted by various transcriptional activators (27, 45, 46) .
Correlation between Dissociation of CDKs and
Transcriptional Activation-The observation of the repressor-like actions of CDK8 and CDK19 led us to hypothesize that these proteins repress C/EBPβ-target gene transcription regardless of nuclear signaling (Fig.  1, C and D) . To further investigate the relationships between transcriptional repression and CDK8/19 dissociation in HeLa S3 cells, we knocked down both CDKs in HeLa S3 cells using siRNAs (Fig. 1F) , and measured IL-8 and TNFα mRNA levels by quantitative PCR (qPCR). The levels of these mRNAs were elevated by CDK8/19 double knockdown in the absence of PMA (Fig. 1E, white bars) . Additionally, knockdown of Mediator CDKs increased the PMA-inducible transcription of those two genes (Fig. 1E, gray bars) . Thus, dissociation of CDK8 and CDK19 from promoters is well correlated with transcriptional activation.
PRMT5 and WDR77 Interact with Both CDK8 and CDK19-To identify CDK8-and/or
CDK19-interacting proteins, we prepared large amounts of CDK8 and CDK19-containing Mediator complexes from HeLa nuclear extracts. These nuclear extracts were prepared from large cultures of previously prepared HA/FLAGtagged CDK8 (HF-CDK8)-and CDK19 (HF-CDK19)-expressing stable cell lines previously established by our group (19, 25) . Each CDKcontaining Mediator complex was purified using anti-FLAG M2 agarose beads (Fig. 2, A and B) . The silver-stained gels of each CDK8-or CDK19-containing Mediator fraction contained unknown bands that could not be considered Mediator subunits based on their molecular masses ( Fig. 2A) . We cut those bands from the gels and subjected them to LC-MS/MS analysis resulting in the identification of the arginine methyltransferase PRMT5 and the WD-repeat protein 77 (WDR77, also called MEP50) as candidates for Mediator CDK-interacting proteins. PRMT5 is a type-II arginine methyltransferase that symmetrically catalyzes the addition of two methyl groups to two arginine guanidino-nitrogen atoms, i.e., the symmetric dimethylation of arginine residues (47) . WDR77 is an important cofactor for PRMT5 catalytic activity (48) . To validate the LC-MS/MS findings, we performed Western blotting on HF-CDK8-and HF-CDK19-containing Mediator complexes from individually prepared nuclear extracts, and we reproducibly detected these specific interactions in other purifications (Fig. 2C) .
To further confirm the interactions between CDK8-or CDK19-containing intact Mediator and the two proteins we identified, we purified CDK8-and CDK19-containing Mediator complexes by HPLC-gel filtration and anti-FLAG M2 agarose chromatography. In the eluate fractions of both CDK8-and CDK19-containing Mediators, we detected PRMT5 and WDR77 along with other Mediator subunits (MED12 and MED15) (Fig. 3, A and B) , indicating that PRMT5 and WDR77 are associated with the Mediator complexes. Next, to determine whether PRMT5 and/or WDR77 bind directly to the two Mediator CDKs, we coexpressed S-tag-fused PRMT5 (S-PRMT5) or WDR77 (S-WDR77) with HF-CDK8 (Fig. 4A) or HF-CDK19 (Fig. 4B) in HeLa S3 cells. Both S-tagged proteins were precipitated with Sprotein-agarose affinity beads. Ectopically expressed CDK8 and CDK19 were coprecipitated only when S-PRMT5 or S-WDR77 was simultaneously expressed. In addition, we showed that bacterially expressed S-PRMT5 or S-WDR77 bound to bacterially expressed GST-CDK8 and GST-CDK19 (Fig. 4C) . These results indicate that PRMT5 and WDR77 bind independently and directly to both CDK8 and CDK19.
CDK8-and CDK19-containing Mediator
Complexes Possess Histone Methyltransferase Activity-PRMT5 plays roles both in the nucleus and the cytoplasm and has various substrates, including histones, cytoplasmic signal transducers, spliceosomal proteins, transcription factors, and PIWI proteins (49) . In the context of transcriptional regulation, histones are particularly well-known targets of PRMT5-directed methylation (39, 50, 51) . The association of PRMT5 with both CDK8 and CDK19 indicates that this histone modifying enzyme has a close relationship with Mediator (Fig. 4, A and B) . To validate the functional role of PRMT5, we assayed the methyltransferase activities of purified HF-CDK8 and HF-CDK19-containing Mediator complexes, and demonstrated that both complexes have histone H4-specific methyltransferase activity (Fig. 4D,  lanes 2 and 3) . The type-II arginine methyltransferase PRMT5 and a group of type-I arginine methyltransferases that catalyze the asymmetric dimethylation of arginine residues share common recognition sequences, including histone arginine residues. Symmetric dimethylation of H4R3 (H4R3me2s) is a known target of PRMT5 that has been linked to transcriptional repression, whereas asymmetric dimethylation of H4R3 (H4R3me2a), which is catalyzed by PRMT1 and PRMT6, is associated with transcriptional activation (52) . To verify the specificity of the Mediator-associated methyltransferase activity for histone H4, we used an H4R3me2s-specific antibody (Abcam) to show that both CDK8-and CDK19-containing Mediator complexes could catalyze the H4R3me2s modification (Fig. 4E ). (39) . Because we suspected that the functional interactions between Mediator CDKs and histone modification enzymes, discussed in the previous section, are involved in Mediator CDKdependent transcriptional repression, we analyzed the occupancy of C/EBPβ-target gene promoters by PRMT5, using ChIP assays (Figs. 5 and 6). These assays revealed that PRMT5 was relatively enriched on C/EBPβ-target gene promoter regions when these promoters were inactivated; furthermore, PMA treatment triggered PRMT5 dissociation from these promoter regions (Fig. 5, left panel) . These dissociations seemed to correlate with the dissociation of CDK8/19 from these regions (Fig.  1, C and D) . In order to study the consequences of PRMT5 dissociation, we determined the modification state and occupancies of these regions by antibodies against H4R3me2s and DNMT3A, respectively (Fig. 5, middle and right  panels) . The H4R3me2s modification signals were detected in both promoter and proteincoding regions (Fig. 5, middle panel) . These signals, especially at the promoter regions, were decreased by PMA treatment. In addition, at the promoter regions, the DNMT3A signals were reduced by PMA treatment, correlating with the H4R3me2s signals at the promoters (Fig. 5, right  panel) . The DNMT3A signals were also detected in the protein-coding regions, again correlating with the H4R3me2s signals. We observed a significant correlation among the changes in the signal intensities of PRMT5, H4R3me2s, and DNMT3A on C/EBPβ-target gene promoters after PMA treatment.
CDK8 and CDK19 Recruit PRMT5 to C/EBPβ-target Gene Promoters-
As shown above, PRMT5 dissociation from the C/EBPβ-target gene promoters was highly correlated with the eviction of CDK8/19 from the promoter regions upon PMA-induced transcriptional activation. These observations suggest that both CDK8 and CDK19 recruit PRMT5 to the C/EBPβ-target gene promoter regions. We depleted CDK8 and CDK19 expression by transfecting HeLa S3 cells with an siRNA mixture against both CDK8 and CDK19, and then measured the occupancy of target gene promoters by each protein using ChIP (Fig. 6) . Depletion of both CDK8 and CDK19 triggered a clear reduction of the CDK8/19 signal in C/EBPβ-target gene promoter regions. CDK8 and CDK19 double-depletion had no effect on PRMT5 and DNMT3A expression levels (Fig.  6C ), but the PRMT5 and DNMT3A signals clearly decreased on C/EBPβ-target gene promoters (Fig. 6, A and B) .
DISCUSSION
How Mediators act both positively and negatively in transcriptional regulation has been a long-standing question (3) . In this study, we investigated the mechanisms of transcriptional repression by large Mediator complexes, which contain the CDK/Cyclin submodule. Mediators play key roles in the regulation of Pol II transcriptional activation by controlling recruitment of the general transcription machinery to promoters (3). Compared to the functional relationships between Mediators and the general transcriptional machinery, the relationships between Mediators and the histone modification factors are less well understood. A previous study demonstrated that MED12, one of the largest Mediator subunits within the CDK/Cyclin submodule, interacts with the repressive histone methyltransferase G9a and represses neuronal gene expression (54) ; this repressive mechanism is representative of the regulation of histone modification machinery by Mediators. We found in HeLa S3 cells that two CDKs, CDK8 and CDK19, each of which can serve as a subunit of canonical holo-Mediator, interact directly with the histone arginine methyltransferase PRMT5 and its cofactor WDR77 to repress transcription.
Dissociation of Mediator CDKs from C/EBPβ-target
Genes Changes the Transcriptional Status from Repression to Activation-We used the phorbol ester PMA transcriptional induction system to study the pivotal role of Mediator CDKs in transcription. Upon PMA treatment of the HeLa S3 cell line, we observed C/EBPβ-dependent transcriptional activation (Fig. 1, A-D) . Mediator CDKs, on the other hand, dissociated from the promoter regions (Fig. 1, C and D) . When both CDKs were knocked down, transcriptional activation was further increased (Fig. 1E) . Our observations clearly indicate that CDK8 and/or CDK19 act as repressors of the C/EBPβ-target genes in the absence of MAPK signaling, and that these CDKs play key roles in the transition from transcriptional repression to activation.
PRMT5 and WDR77 are Mediator CDKinteracting Proteins-To determine which proteins cause Mediator CDK-dependent transcriptional repression, we tried to identify CDK8-and/or CDK19-interacting proteins from purified CDK-containing Mediator complexes ( Fig. 2A) . We identified two proteins, the histone arginine methyltransferase PRMT5 and the WDrepeat protein WDR77, as both CDK8-and CDK19-containing Mediator-interacting proteins. We further characterized these interactions using two step-purified CDK-containing Mediator complexes, and demonstrated that both PRMT5 and WDR77 stably associate with both types of CDK-containing Mediators (Fig. 3, A and B) . These data indicate that PRMT5 and WDR77 bind to both CDK8-and CDK19-containing Mediators. Further biochemical analyses proved that both PRMT5 and WDR77 bound directly to CDK8 and CDK19 (Fig. 4, A-C) . Taken together, these results clearly demonstrated that the two Mediator CDKs directly interact with PRMT5 as well as WDR77.
A Transcriptional Repression Model of C/EBPβ-target Genes by CDK-containing
Mediators-Both CDK8 and CDK19-containing Mediator fractions possessed histone H4 arginine 3 symmetric dimethylation (H4R3me2s) activity (Fig. 4, D and E) . Based on the ChIP analyses, dissociation of CDK8 and CDK19 from promoters, dissociation of PRMT5 from promoters, and reduction of the H4R3me2s modification at promoters were mutually correlated (Figs. 5 and 6 ). These results clearly indicate that the H4R3me2s activity of the two CDK-containing Mediators is primarily due to their interactions with PRMT5. This specificity implies that the transcriptionally repressive functions of Mediator CDKs stem from histone modifications that repress transcription. In addition, these events were highly correlated with DNMT3A binding at the promoter regions of four C/EBPβ-target genes (Figs. 5 and 6) (39). These results indicate that DNMT3A recruitment leads to the repression of target gene transcription. Taking all of these findings into consideration, we propose a novel model for transcriptional repression by Mediator CDKs (Fig. 7): i) The large Mediator complex containing the CDK/cyclin submodule, which binds to C/EBPβ, associates with PRMT5 (and WDR77).
ii) PRMT5 symmetrically dimethylates histone H4R3 (H4R3me2s). iii) The DNA methyltransferase DNMT3A then targets this methylated H4R3 to bind and methylate CpG islands around the promoter region. iv) As a consequence, these three sequential events cause transcriptional repression of C/EBPβ-target genes. In the near future, this model might help to solve several mechanistic questions regarding Mediator-based gene repression.
Regulation of H4R3me2s Modification
Independent of PRMT5 Recruitment-We showed that the two Mediator CDKs physically interact with PRMT5 and WDR77 in HeLa S3 cells. The CDK8/19 occupancies of both gene promoters tested decreased to the background level (defined as exonic signals) after PMA treatment (Fig. 1, C and D) . The reduced PRMT5 signal on promoters after PMA treatment was highly correlated with the CDK8/19 signals (Fig. 5) . However, the H4R3me2s signal exhibited little correlation with the PRMT5 signal. In particular, at the TNFα gene promoter region, the PRMT5 signal was reduced 70-80% by PMA treatment, whereas H4R3me2s modification in this region was reduced only 20%. In exonic regions, there was a 20-40% change in the PRMT5 signal after PMA treatment, but H4R3me2s signals in exons were almost equal to those on the promoter. We suspect two underlying mechanisms caused this difference between PRMT5 occupancies and H4R3me2s modifications. First, the H4R3 residue can also be symmetrically methylated by the type-II arginine methyltransferase PRMT7 (55); thus, in exonic regions, PRMT7 activity maycompensate for loss of PRMT5. Second, we suspect the effects of competing regulation by opposing histone demethylases. A recent study showed that H4R3me2s is demethylated by Jumonji domain-containing 6 (JMJD6) (56) . Based on the low occupancy of PRMT5 at exonic regions, we hypothesize that H4R3me2s modifications in exonic regions may be regulated by PRMT7 and/or another novel methyltransferase, rather than by PRMT5. Given that histone methylation is competitively or collaboratively regulated by multiple factors, we also suspect that H4R3me2s modifications in the TNFα promoter region are collaboratively regulated by other histone modification factors.
In the future, there should be more detailed investigations into the underlying coordination of such factors.
Downstream Mechanism of CDK8 and CDK19-dependent DNMT3A Recruitment-PRMT5 is a transcriptionally repressive histone modification enzyme, and its modifications of H4R3me2s act repressively when recognized by DNMT3A (39) . In addition, H4R3me2s modifications are localized to repressive regions of chromosomes (53) . Our results demonstrate that histone demethylation and transcriptional activation of C/EBPβ-target genes occurs within less than 2 h. Although our results demonstrate a relationship between it seems likely that DNA methylation-independent transcriptional repression is also involved in the transcriptional repression of C/EBPβ-target genes by Mediator CDKs. Indeed, DNMT3A interacts with the histone deacetylase HDAC1, as well as with the repressive histone methyltransferases (HMTs) SUV39H1 and SETDB1 (57, 58) . These interactions with HDAC1 and/or HMTs might repress C/EBPβ-target gene transcription. siRNA-mediated knockdown of CDK8 and CDK19 promoted PRMT5 dissociation from the promoter, similar to the effect of PMA treatment, clearly indicating that PRMT5 is recruited to C/EBPβ-target gene promoter regions by Mediator CDKs, and may repress target gene transcription via DNMT3A, as proposed in the model shown in Fig. 7 .
Potential Functional Differences between CDK8 and CDK19-Even in light of the model we propose, questions remain regarding the functions of Mediator CDKs during transcriptional regulation. In the regulation of several types of immediate-early gene expression, CDK8 acts as a transcriptional activator (19, 21, 59) . The functional bivalency of CDK8 is quite enigmatic, but structural studies may provide a clue. Mediators exhibit a structural change when they bind various types of transcriptional activators (60) , and therefore exist as multiple structurally distinct subcomplexes. Some of these subcomplexes may bind tightly to PRMT5 and act as corepressors, as described in this paper, whereas others may lack PRMT5 and act as coactivators. On the other hand, the CDK/Cyclin submodule functions in transcriptional activation of immediate-early genes in a Mediator-independent manner (59). We observed that PRMT5 bound holo-Mediator complexes (Figs. 2-4) , pointing to the need for further studies into the functional differences between CDK8-and CDK19-containing Mediators, as well as the functions of the free forms of the two CDK/Cyclin heterodimers. PRMT5 also symmetrically dimethylates histone H3 arginine 2 (H3R2me2s) (61) . In contrast to H4R3me2s, H3R2me2s activates transcription by recruiting WDR5 and causing the methyltransferase complex MLL to trimethylate H3K4. Therefore, an additional regulatory mechanism probably underlies the specificity of PRMT5 histone modification.
Our study demonstrated that Mediator CDKs play regulatory roles in both histone modification and transcription of C/EBPβ-target genes. In addition, we attempted to characterize the functions of Mediator CDKs at C/EBPβ-target genes in HeLa S3 cells by performing microarray analysis (Table 1) ; the results showed that the repressive target genes of Mediator CDKs were highly correlated with the target genes of C/EBPβ. In future studies, we will use CDK-knockout mice to understand the roles of Mediators in imortant physiological processes. A total of 197 transcripts were identified as significantly changed relative to the negative control. These transcripts were analyzed using the Ingenuity Pathway Analysis software to categorize them according to their pathways (significance P<0.05). The numbers of genes from the C/EBPβ and NF-κB target gene pathways are shown. 
Type of gene
